Table 1 Cancer and treatment characteristics of the study population
Characteristics | |
|---|---|
Median age at the time of diagnosis (years; range) | 70.9 (46.1–89.0) |
T stage, n (%) | |
T1 | 347 (52.2%) |
T2a-b | 62 (9.3%) |
T2c | 92 (13.8%) |
T3 | 147 (22.1%) |
T4 | 16 (2.4%) |
unknown | 1 (0.15%) |
N1-disease, n (%) | 5 (0.75%) |
Gleason score, n (%) | |
6 | 211 (31.7%) |
7 | 260 (39.1%) |
8 | 53 (8.0%) |
9 | 138 (20.8%) |
10 | 3 (0.45%) |
Percentage of positive biopsy cores, n (%) | |
1–10% | 65 (9.8%) |
11–20% | 95 (14.3%) |
21–30% | 82 (12.3%) |
31–40% | 63 (9.5%) |
41–50% | 108 (16.2%) |
51–60% | 45 (6.8%) |
61–70% | 32 (4.8%) |
71–80% | 20 (3.0%) |
81–90% | 30 (4.5%) |
91–100% | 67 (10.1%) |
Diagnostic transurethral resection of the prostate (TURP) | 9 (1.4%) |
Missing data | 49 (7.4%) |
Median PSA-level at the time of the diagnosis (range) | 9.0 (0.9–694.0) |
Median time from diagnosis to EBRT, months (range) | 3.80 (0.77–83.6) |
Median duration of ADT, months (range) | 20.0 (1.6–125.7) |
Fractionation type, n (%) | |
conventional | 633 (95.2%) |
hypofractionated | 32 (4.8%) |
Average performance status (ECOG score), n (%) | |
0 | 348 (52.3%) |
1 | 281 (42.3%) |
2 | 33 (5.0%) |
3 | 3 (0.45%) |
Charlson Comorbidity Index, n (%) | |
0 | 298 (44.8%) |
1 | 190 (28.6%) |
2 | 98 (14.7%) |
3 | 37 (5.6%) |
4 | 20 (3.0%) |
5 | 13 (2.0%) |
6 | 6 (0.90%) |
7 | 2 (0.30%) |
8 | 1 (0.15%) |